Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Daiichi Sankyo
With
Shanghai Sankyo Pharmaceuticals Co., Ltd.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
At Visit 3, mean seated diastolic blood pressure (SeDBP) ≥ 95 mmHg and \< 110 mmHg, AND mean seated systolic blood pressure (SeSBP) ≥140 mmHg and \< 180 mmHg
At Visit 4, mean SeDBP ≥ 90 mmH
No significant disorder in blood, kidney, liver, cardiovascular system or endocrinology system
You may not be if
Patients with known or suspect secondary hypertension
Unstable angina
History of acute myocardial infarct, or PTCA or surgical cardiac procedures 3 months before entry into this study
Prior or current congestive heart failure (NYHA grade III or IV), hypertrophic obstructive cardiomyopathy, valvular disease or rheumatic heart disease
Gout sufferers, even with the normal serum uric acid at entry
Retinal hemorrhage /exudate
Type 1 diabetes mellitus
Uncontrolled type 2 diabetes mellitus
Hypovolemia
Patients with autoimmune disease
Clareo Health | Evaluation of the Additional Efficacy, and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension
